Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease

Clinical Biochemistry

Volumn 43, Issue 1-2, 2010, Pages 57-62

  Wainstein, Rodrigo V ^a   Wainstein, Marco V ^a   Ribeiro, Jorge P ^a,b   Dornelles, Laura V ^a   Tozzati, Paula ^a   Ashton Prolla, Patrícia ^b   Ewald, Ingrid P ^b   Vietta, Giovana ^a   Polanczyk, Carisi A ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Angiography; Genetics; Inflammation; Ischemic heart disease; Polymorphism

Indexed keywords

ADENOSINE; GUANOSINE; MYELOPEROXIDASE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 72649085189     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.07.022     Document Type: Article

References (37)

1. Nicholls S.J., and Hazen S.L. Myeloperoxidase and cardiovascular disease. Artherioscler. Thromb. Vasc. Biol. 25 (2005) 1102-1111
2. Hansson G.K. Inflammation, atherosclerosis, and coronary heart disease. N. Engl. J. Med. 352 (2005) 1685-1695
3. Daugherty A., Dunn J.L., Rateri D.L., and Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94 (1994) 437-444
4. Podrez E.A., Schmitt D., Hoff H.F., and Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103 (1999) 1547-1560
5. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114 (2004) 529-541
6. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 100 (1997) 2153-2157
7. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296 (2002) 2391-2394
8. Vita J.A., Brennan M.L., Gokce N., et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110 (2004) 1134-1139
9. Baldus S., Heitzer T., Eiserich J.P., et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic. Biol. Med. 37 (2004) 902-911
10. Fu X., Kassim S.Y., Parks W.C., and Heinecke J.W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J. Biol. Chem. 278 (2003) 28403-28409
11. Sugiyama S., Kugiyama K., Aikawa M., Nakamura S., Ogawa H., and Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase mediated oxidant in plaque erosion and thrombogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1309-1314
12. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1143-1146
13. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 (2001) 2136-2142
14. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
15. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349 (2003) 1595-1604
16. Cavusoglu E., Ruwende C., Eng C., et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am. J. Cardiol. 99 (2007) 1364-1368
17. Mocatta T.J., Pilbrow A.P., Cameron V.A., et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49 (2007) 1993-2000
18. Vasilyev N., Williams T., Brennan M.L., et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112 (2005) 2812-2820
19. Kutter D., Devaquet P., Vanderstocken G., Paulus J.M., and Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol. 104 (2000) 10-15
20. Piedrafita F.J., Molander R.B., Vansant G., Orlova E.A., Pfahl M., and Reynolds W.F. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroidhormone-retinoic acid response element. J. Biol. Chem. 271 (1996) 14412-14420
21. Nikpoor B., Turecki G., Fournier C., Theroux P., and Rouleau G.A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am. Heart J. 142 (2001) 336-339
22. Pecoits-Filho R., Stenvinkel P., Marchlewska A., et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. Suppl. (2003) S172-S176
23. Makela R., Laaksonen R., Janatuinen T., et al. Myeloperoxidase gene variation and coronary flow reserve in young healthy men. J. Biomed. Sci. 11 (2004) 59-64
24. Asselbergs F.W., Reynolds W.F., Cohen-Tervaert J.W., Jessurun G.A., and Tio R.A. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am. J. Med. 116 (2004) 429-430
25. Mäkelä R., Karhunen P.J., Kunnas T.A., et al. Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study. Lab. Invest. 83 (2003) 919-925
26. Mäkelä R., Loimaala A., Nenonen A., et al. The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes. Clin. Biochem. 41 (2008) 532-537
27. Garcia S., Canoniero M., Peter A., Marchena E., and Ferreira A. Correlations of TIMI Risk Score with angiographic severity and extent of coronary artery disease in patients with non-ST-elevation acute coronary syndromes. Am. J. Cardiol. 93 (2004) 813-816
28. Reynolds W.F., Chang E., Douer D., Ball E.D., and Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 90 (1997) 2730-2737
29. Chevrier I., Tregouet D.A., Massonnet-Castel S., Beaune P., and Loriot M.A. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis?. Atherosclerosis 188 (2006) 150-154
30. Hoy A., Tregouet D., Leininger-Muller B., et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur. J. Hum. Genet. 9 (2001) 780-786
31. Rutgers A., Heeringa P., Giesen J.E., Theunissen R.T., Jacobs H., and Tervaert J.W. Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br. J. Haematol. 123 (2003) 536-538
32. Borges FK, Borges FK, Stella SF, et al. Serial analysis of myeloperoxidase and C-reactive protein in patients with acute coronary syndrome. Clin. Cardiol. in press.
33. Ndrepepa G., Braun S., Mehilli J., et al. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur. J. Clin. Invest. 38 (2008) 90-96
34. Duzgunçinar O., Yavuz B., Hazirolan T., et al. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol. 63 (2008) 147-152
35. Kubala L., Lu G., Baldus S., Berglund L., and Eiserich J.P. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin. Chim. Acta 394 (2008) 59-62
36. Roman R.M., Wendland A.E., and Polanczyk C.A. Myeloperoxidase and coronary arterial disease: from research to clinical practice. Arq. Bras. Cardiol. 91 1 (2008 Jul) e11-9
37. Stefanescu A., Braun S., Ndrepepa G., et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am. Heart J. 155 (2008) 356-360